Anne White to retire as head of Lilly Neuroscience after three decades at company
Eli Lilly and Company has announced that Anne White, executive vice president and president of...
Read More
Tag: eli lilly
ADDF reflects on Eli Lilly’s donanemab
Company’s phase 3 research showed the importance of running biomarker-powered clinical trials
Read More
AbbVie and Eli Lilly snub drug pricing agreement
Major industry names depart leaving UK pricing deal in serious jeopardy
Read More
Eli Lilly receives marketing authorisation for baricitinib
Treatment involves adult patients with severe alopecia areata
Read More
NICE recommends Eli Lilly’s breast cancer therapy
Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence
Read More
MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
Authorisation of the treatment is based on results from the phase 3 trial
Read More
First treatment for adults across full spectrum of chronic heart failure
Largest unmet need in cardiovascular medicine finally receives approved therapy
Read More
NICE recommends Eli Lilly’s breast cancer drug Verzenios
Cost-effectiveness watchdog initially rejected the drug in February
Read More
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients
Read More
NICE backs Lilly’s Taltz for axial spondyloarthritis
Drug has been cleared for use in patients whose condition is not controlled well enough with conventional therapy
Read More
Lilly, Incyte report positive results for baricitinib in alopecia areata
Oral JAK inhibitor improved hair regrowth across both dosing groups
Read More
Lilly’s mirikizumab hits primary endpoint in ulcerative colitis study
Patients treated with monoclonal antibody achieved clinical remission at week 12
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
